Astragalus Polysaccharides 500 mg

DRUG5 trials

Sponsors

PhytoHealth Corporation, Taipei Medical University

Conditions

Cancer-related FatigueNeutropenia, MalignantSurvivalTumor, Esophageal

Phase 2

A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

TerminatedNCT01720563

PhytoHealth CorporationCancer-related Fatigue

Start: 2012-12-31End: 2014-04-30Updated: 2025-06-04

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

CompletedNCT03314805

PhytoHealth CorporationCancer-related Fatigue, Neutropenia, Malignant

Start: 2018-03-01End: 2021-08-27Updated: 2025-06-04

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

CompletedNCT03611712

PhytoHealth CorporationCancer-related Fatigue, Survival, Tumor, Esophageal

Start: 2019-02-19End: 2025-03-05Updated: 2025-06-04

Phase 4

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

CompletedNCT01720550

PhytoHealth CorporationCancer-related Fatigue

Start: 2012-11-30End: 2017-06-30Updated: 2025-06-04

Unknown Phase

Effects of PG2 on Fatigue-Related Symptom Clusters

CompletedNCT02740959

Taipei Medical UniversityCancer-related Fatigue

Start: 2016-03-31End: 2017-05-08Updated: 2018-09-12

Related Papers

Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer.

2024-10-2812 citations

Effect of astragalus polysaccharides (PG2) treatment of adjuvant chemotherapy-induced fatigue in premenopausal patients with breast cancer.

Journal of Clinical Oncology2023-06-012 citations

PG2 injection, a novel botanical drug approved for improving cancer-related fatigue among advanced cancer patients under standard palliative care: A double blind, multi-center, randomized phase IV study.

Journal of Clinical Oncology2018-05-20